pyridoxamine has been researched along with Alloxan Diabetes in 20 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our data indicate a protective effect of pyridoxamine against diabetes-induced cognitive deficits, and our comprehensive 'omics datasets provide insight into the pathogenesis of cognitive dysfunction enabling development of further mechanistic and therapeutic studies." | 7.91 | Cognitive dysfunction in diabetic rats is prevented by pyridoxamine treatment. A multidisciplinary investigation. ( Begley, P; Chevalier-Riffard, C; Church, SJ; Cooper, GJS; Dowsey, AW; Gardiner, NJ; Grayson, B; Kassab, S; Neill, JC; Phillips, AM; Rotariu, SM; Unwin, RD; Zeef, LAH, 2019) |
| " In the current manuscript, we studied the effect of pyridoxamine (PM) on protein glycation, oxidative stress, interleukin-1α (IL-1α), IL-6, C-reactive protein (CRP), gene expression of tumour necrosis factor-α (TNF-α) and transforming growth factor-β1 (TGF-β1) in relation to microalbuminuria and kidney functions in a model of alloxan-induced diabetic rats." | 7.79 | Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflammatory cytokines in experimental diabetic nephropathy. ( Elseweidy, MM; Elswefy, SE; Younis, NN; Zaghloul, MS, 2013) |
| "Our data indicate a protective effect of pyridoxamine against diabetes-induced cognitive deficits, and our comprehensive 'omics datasets provide insight into the pathogenesis of cognitive dysfunction enabling development of further mechanistic and therapeutic studies." | 3.91 | Cognitive dysfunction in diabetic rats is prevented by pyridoxamine treatment. A multidisciplinary investigation. ( Begley, P; Chevalier-Riffard, C; Church, SJ; Cooper, GJS; Dowsey, AW; Gardiner, NJ; Grayson, B; Kassab, S; Neill, JC; Phillips, AM; Rotariu, SM; Unwin, RD; Zeef, LAH, 2019) |
| " In the current manuscript, we studied the effect of pyridoxamine (PM) on protein glycation, oxidative stress, interleukin-1α (IL-1α), IL-6, C-reactive protein (CRP), gene expression of tumour necrosis factor-α (TNF-α) and transforming growth factor-β1 (TGF-β1) in relation to microalbuminuria and kidney functions in a model of alloxan-induced diabetic rats." | 3.79 | Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflammatory cytokines in experimental diabetic nephropathy. ( Elseweidy, MM; Elswefy, SE; Younis, NN; Zaghloul, MS, 2013) |
| "It appears that pyridoxamine ameliorated lipid peroxidation and insulin resistance in KK-A(y)/Ta mice." | 3.75 | Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-Ay/Ta mice. ( Gohda, T; Hagiwara, S; Horikoshi, S; Ishikawa, Y; Murakoshi, M; Ohara, I; Tanimoto, M; Tomino, Y; Toyoda, H, 2009) |
| "Pyridoxamine is a post-Amadori AGE inhibitor-that is, an "Amadorin"-whereas aminoguanidine primarily scavenges reactive dicarbonyl precursors to AGEs." | 2.43 | Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design. ( Chen, Y; Khalifah, RG; Wassenberg, JJ, 2005) |
| "Levels of blood glycation and disc degeneration were investigated." | 1.56 | Advanced Glycation End Product Inhibitor Pyridoxamine Attenuates IVD Degeneration in Type 2 Diabetic Rats. ( Avalos, P; Bae, HW; Glaeser, JD; Ju, D; Kaneda, G; Kanim, LEA; Metzger, MF; Salehi, K; Sheyn, D; Stefanovic, T; Stephan, S; Tawackoli, W; Yang, JH, 2020) |
| "Pyridoxamine was used as the antagonist of advanced glycation end products (AGEs)." | 1.42 | Advanced glycation end products induced immune maturation of dendritic cells controls heart failure through NF-κB signaling pathway. ( Cao, W; Chen, J; Chen, S; Chen, X; Chen, Y; Huang, H; Liu, P, 2015) |
| "Pyridoxamine treatment did not restore erythrocyte glutathione (which was reduced by almost half) in diabetic animals, but it enhanced erythrocyte glyoxalase I activity." | 1.31 | Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal. ( Biemel, KM; Lederer, MO; Mally, A; Nagaraj, RH; Padayatti, PS; Sarkar, P, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (45.00) | 29.6817 |
| 2010's | 8 (40.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sousa, AS | 1 |
| Passos, MP | 1 |
| Ruberti, OM | 1 |
| Jarrete, AP | 1 |
| Delbin, MA | 1 |
| Kassab, S | 1 |
| Begley, P | 1 |
| Church, SJ | 1 |
| Rotariu, SM | 1 |
| Chevalier-Riffard, C | 1 |
| Dowsey, AW | 1 |
| Phillips, AM | 1 |
| Zeef, LAH | 1 |
| Grayson, B | 1 |
| Neill, JC | 1 |
| Cooper, GJS | 1 |
| Unwin, RD | 1 |
| Gardiner, NJ | 1 |
| Glaeser, JD | 1 |
| Ju, D | 1 |
| Tawackoli, W | 1 |
| Yang, JH | 1 |
| Salehi, K | 1 |
| Stefanovic, T | 1 |
| Kanim, LEA | 1 |
| Avalos, P | 1 |
| Kaneda, G | 1 |
| Stephan, S | 1 |
| Metzger, MF | 1 |
| Bae, HW | 1 |
| Sheyn, D | 1 |
| Jiang, M | 1 |
| Yakupu, A | 1 |
| Guan, H | 1 |
| Dong, J | 1 |
| Liu, Y | 1 |
| Song, F | 1 |
| Tang, J | 1 |
| Tian, M | 1 |
| Niu, Y | 1 |
| Lu, S | 1 |
| Chiazza, F | 1 |
| Cento, AS | 1 |
| Collotta, D | 1 |
| Nigro, D | 1 |
| Rosa, G | 1 |
| Baratta, F | 1 |
| Bitonto, V | 1 |
| Cutrin, JC | 1 |
| Aragno, M | 1 |
| Mastrocola, R | 1 |
| Collino, M | 1 |
| Illien-Junger, S | 1 |
| Grosjean, F | 1 |
| Laudier, DM | 1 |
| Vlassara, H | 1 |
| Striker, GE | 1 |
| Iatridis, JC | 1 |
| Elseweidy, MM | 1 |
| Elswefy, SE | 1 |
| Younis, NN | 1 |
| Zaghloul, MS | 1 |
| Madu, H | 1 |
| Avance, J | 1 |
| Chetyrkin, S | 1 |
| Darris, C | 1 |
| Rose, KL | 1 |
| Sanchez, OA | 1 |
| Hudson, B | 1 |
| Voziyan, P | 1 |
| Cao, W | 1 |
| Chen, J | 1 |
| Chen, Y | 2 |
| Chen, S | 1 |
| Chen, X | 1 |
| Huang, H | 1 |
| Liu, P | 1 |
| Ren, X | 1 |
| Sun, H | 1 |
| Zhang, C | 1 |
| Li, C | 1 |
| Wang, J | 1 |
| Shen, J | 1 |
| Yu, D | 1 |
| Kong, L | 1 |
| Murakoshi, M | 1 |
| Tanimoto, M | 1 |
| Gohda, T | 1 |
| Hagiwara, S | 1 |
| Ohara, I | 1 |
| Toyoda, H | 1 |
| Ishikawa, Y | 1 |
| Horikoshi, S | 1 |
| Tomino, Y | 1 |
| Chang, KC | 1 |
| Liang, JT | 1 |
| Tsai, PS | 1 |
| Wu, MS | 1 |
| Hsu, KL | 1 |
| Moore, CJ | 1 |
| Shao, CH | 1 |
| Nagai, R | 1 |
| Kutty, S | 1 |
| Singh, J | 1 |
| Bidasee, KR | 1 |
| Stitt, A | 1 |
| Gardiner, TA | 1 |
| Alderson, NL | 3 |
| Canning, P | 2 |
| Frizzell, N | 2 |
| Duffy, N | 1 |
| Boyle, C | 1 |
| Januszewski, AS | 2 |
| Chachich, M | 1 |
| Baynes, JW | 3 |
| Thorpe, SR | 3 |
| Anderson, NL | 1 |
| Chachich, ME | 1 |
| Metz, TO | 1 |
| Youssef, NN | 1 |
| Stitt, AW | 1 |
| Khalifah, RG | 1 |
| Wassenberg, JJ | 1 |
| Cameron, NE | 1 |
| Gibson, TM | 1 |
| Nangle, MR | 1 |
| Cotter, MA | 1 |
| Padival, S | 1 |
| Nagaraj, RH | 2 |
| Degenhardt, TP | 1 |
| Arrington, DD | 1 |
| Beattie, RJ | 1 |
| Basgen, JM | 1 |
| Steffes, MW | 1 |
| Sarkar, P | 1 |
| Mally, A | 1 |
| Biemel, KM | 1 |
| Lederer, MO | 1 |
| Padayatti, PS | 1 |
2 reviews available for pyridoxamine and Alloxan Diabetes
| Article | Year |
|---|---|
Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Drug Design; Glycation End Product | 2005 |
Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diabetic Neuropathies; Glycation En | 2005 |
18 other studies available for pyridoxamine and Alloxan Diabetes
| Article | Year |
|---|---|
Evaluation of coronary function in female rats with severe type 1 diabetes: Effects of combined treatment with insulin and pyridoxamine.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Female; Glucose; Insulin; NF-ka | 2023 |
Cognitive dysfunction in diabetic rats is prevented by pyridoxamine treatment. A multidisciplinary investigation.
Topics: Animals; Cognitive Dysfunction; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Male; Pyridoxa | 2019 |
Advanced Glycation End Product Inhibitor Pyridoxamine Attenuates IVD Degeneration in Type 2 Diabetic Rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; | 2020 |
Pyridoxamine ameliorates methylglyoxal-induced macrophage dysfunction to facilitate tissue repair in diabetic wounds.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Macrophages; Mice; Pyridoxamine | 2022 |
Protective Effects of Pyridoxamine Supplementation in the Early Stages of Diet-Induced Kidney Dysfunction.
Topics: Albumins; Animals; Body Weight; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; | 2017 |
Combined anti-inflammatory and anti-AGE drug treatments have a protective effect on intervertebral discs in mice with diabetes.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Diabetes Mellitus, Experimental; Disease Mo | 2013 |
Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflammatory cytokines in experimental diabetic nephropathy.
Topics: Albuminuria; Alloxan; Animals; C-Reactive Protein; Cytokines; Diabetes Mellitus, Experimental; Diabe | 2013 |
Pyridoxamine protects proteins from damage by hypohalous acids in vitro and in vivo.
Topics: Amino Acid Sequence; Animals; Bromates; Chromatography, Liquid; Collagen Type IV; Diabetes Mellitus, | 2015 |
Advanced glycation end products induced immune maturation of dendritic cells controls heart failure through NF-κB signaling pathway.
Topics: Animals; Bone Marrow; Cardiotonic Agents; Cell Differentiation; Coculture Techniques; Dendritic Cell | 2015 |
Protective function of pyridoxamine on retinal photoreceptor cells via activation of the p‑Erk1/2/Nrf2/Trx/ASK1 signalling pathway in diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease M | 2016 |
Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-Ay/Ta mice.
Topics: Adipose Tissue; Animals; CD36 Antigens; Diabetes Complications; Diabetes Mellitus, Experimental; Dia | 2009 |
Prevention of arterial stiffening by pyridoxamine in diabetes is associated with inhibition of the pathogenic glycation on aortic collagen.
Topics: Animals; Aorta; Arteries; Cardiac Output; Cardiomegaly; Collagen; Diabetes Mellitus, Experimental; G | 2009 |
Malondialdehyde and 4-hydroxynonenal adducts are not formed on cardiac ryanodine receptor (RyR2) and sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA2) in diabetes.
Topics: Aldehydes; Animals; Arginine; Calcium; Cyclic N-Oxides; Diabetes Mellitus, Experimental; Diabetic Ca | 2013 |
The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes.
Topics: Animals; Capillaries; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Extracellular Matrix; F | 2002 |
Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, E | 2004 |
Pyridoxamine inhibits maillard reactions in diabetic rat lenses.
Topics: Aldehyde Reductase; Animals; Arginine; Chromatography, High Pressure Liquid; Diabetes Complications; | 2006 |
Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.
Topics: Animals; Collagen; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Fem | 2002 |
Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal.
Topics: Animals; Arginine; Cattle; Chromatography, High Pressure Liquid; Crystallins; Diabetes Mellitus, Exp | 2002 |